Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Cardiovasc Drugs Ther ; 25(3): 243-50, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21584633

RESUMO

PURPOSE: The objective of our study was to identify changes in the coagulation and serum concentration of soluble P-selectin (sP-sel) after i.v. bolus of 0.75 mg/kg enoxaparin in a group of 33 patients during PCI. METHODS AND RESULTS: As compared to baseline, i.v. enoxaparin increased anti -Xa activity and FIIa inhibition together with APTT and thrombin time tests within 20 min, that persisted for 60 min. At 6 h, the results of all tests had returned to baseline. In contrast, the level of prothrombin fragments (F1 + 2) decreased persistingly for a period of 6 h (baseline 1.19 ± 0.42 nmol/l, after 20 min 1.03 ± 0.46 nmol/l, after 60 min 1.06 ± 0.43 nmol/l, after 6 h 0.95 ± 0.40 nmol/l, p < 0.001 vs. baseline for all values). In addition, i.v. enoxaparin decreased serum sP-sel level (baseline 111.80 ± 37.05 ng/ml, after 20 min 87.80 ± 33.17 ng/ml, after 60 min 86.45 ± 29.15 ng/ml, after 6 h 92.24 ± 31.34 ng/ml, p < 0.001 vs. baseline value for all). sP-sel level mildly correlated with both F Xa inhibition (r = -0.275, p < 0.05) and F1 + 2 level (r = 0.274, p < 0.05). CONCLUSION: Intravenous enoxaparin induced target F Xa inhibition (>0.6 IU/ml) for 60 min in 82% of study patients. During the 6 h of monitoring, a decrease of thrombin generation (F1 + 2) and sP-selectin levels were observed.


Assuntos
Angioplastia Coronária com Balão/métodos , Enoxaparina/farmacologia , Selectina-P/efeitos dos fármacos , Trombina/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/farmacologia , Doença da Artéria Coronariana/terapia , Inibidores do Fator Xa , Feminino , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Selectina-P/metabolismo , Tempo de Tromboplastina Parcial , Protrombina/antagonistas & inibidores , Trombina/metabolismo , Tempo de Trombina , Fatores de Tempo
2.
Cas Lek Cesk ; 146(7): 597-602, 2007.
Artigo em Cs | MEDLINE | ID: mdl-17722847

RESUMO

Patients with severe sepsis are at increased risk for developing thrombembolic phenomena. This article aims to clarify the association between systemic inflammation activation and coagulation, pathogenesis of coagulation abnormalities during severe sepsis. The article reviews incidence and deep venous thrombosis risk factors among these patients and summarizes recent evidence-based guidelines for deep venous thrombosis prophylaxis.


Assuntos
Embolia Pulmonar/etiologia , Sepse/complicações , Trombose Venosa/etiologia , Coagulação Sanguínea , Humanos , Embolia Pulmonar/prevenção & controle , Sepse/sangue , Trombose Venosa/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA